Primobolan

evidence score

anabolic

Scheduled Substance

78 studies

Metenolone EnanthateMetenolone AcetatePrimo+1 more

Primobolan (Metenolone) is a mild anabolic steroid available as injectable enanthate and oral acetate forms. DHT-derivative with no aromatization, low androgenicity, and minimal hepatotoxicity (particularly the injectable form). Historically used for muscle wasting, osteoporosis, and malnutrition. Known for "quality" lean muscle gains with minimal water retention and low side effect profile compared to other anabolics. Immune-modulating properties documented. Long associated with elite athletics due to perceived "clean" profile. Still causes HPG suppression. Schedule III controlled substance.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

Approved

Research Sync

Feb 19, 2026

Dosing

Typical

400 mg

200 mgRange800 mg

FrequencyInjectable: once weekly IM. Oral: 50–150mg/day

Set height & weight in Settings to see your dose.

Pharmacology

Half-life10–14 days (enanthate); 4–6 hours (acetate oral)

Onset3–4 weeks for noticeable muscle changes

DurationSuppression recovery 6–8 weeks post-cycle

Routes

intramuscular

oral

Evidence Score

Level B — Moderate

78 studies indexed

Scoring Factors

Volume(40%)~38/100

Quality(30%)~40/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Primobolan is currently categorized as a anabolic compound.

Evidence is moderate (64/100): promising signal from 78 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

DHT-derived anabolic; binds AR without aromatization; no estrogenic activity; anabolic with low androgenicity; notable immune-modulatory effects

Practical Context

Strongest current signals

Level D: Metabolic and Immunomodulatory Effects of α-Ketoglutarate in Burn Injuries: A Systematic Review.
Level D: Ex Vivo Preservation in Vascularized Composite Allotransplantation: State of the Art, Challenges, and Perspectives.
Level D: This review summarizes the current evidence regarding the physiological mechanisms, implementation strategies, clinical outcomes, and safety considerations of IF in the intensive care setting to provide a theoretical basis for further validation of the safety efficacy of the intermittent fasting paradigm for use in the ICU.